Literature Analysis: CK18-M30 Rabbit Monoclonal Antibody Enhances Diagnostic Accuracy in NAFLD

1. Literature Information

Article Topic: The value of CK18-M30 as a non-invasive biomarker in improving the differential diagnosis of non-alcoholic fatty liver disease (NAFLD)

Core Target: To evaluate the ability of CK18-M30 to distinguish simple fatty liver from non-alcoholic steatohepatitis (NASH)

Detection Tool: Anti-CK18-M30 recombinant rabbit monoclonal antibody

Application Scenario: Liver histopathology evaluation, serum non-invasive detection, and disease activity assessment

2. Research Background

Non-alcoholic fatty liver disease (NAFLD) has become one of the most prevalent chronic liver diseases worldwide. Its spectrum ranges from simple hepatic steatosis to non-alcoholic steatohepatitis (NASH), which can further progress to liver fibrosis, cirrhosis, and even hepatocellular carcinoma.

The current “gold standard” for diagnosis is liver biopsy, which is invasive, prone to sampling error, and difficult to use repeatedly. Traditional liver function markers lack sufficient sensitivity and specificity to distinguish simple steatosis from steatohepatitis. Therefore, there is an urgent clinical need for non-invasive, accurate, and stable biomarkers to assess liver injury severity and disease activity.

3. Research Idea

This study focuses on the specific apoptotic fragment of hepatocytes: cytokeratin 18 (CK18), which is cleaved by caspase to produce the M30 neoepitope. This fragment is specifically released into the blood during hepatocyte apoptosis.

By using a high-specificity recombinant rabbit monoclonal antibody targeting the CK18-M30 neoepitope, the research aims to establish an immunological detection method to quantitatively evaluate the degree of hepatocyte apoptosis, so as to achieve non-invasive differential diagnosis and severity assessment of NAFLD/NASH.

4. Research Results

• CK18-M30 is a specific biomarker of hepatocyte apoptosis, and its expression level is significantly elevated in NASH patients.
• It can effectively distinguish simple steatosis from NASH, with higher diagnostic efficiency than traditional liver enzymes.
• The level of serum CK18-M30 is positively correlated with histological inflammatory activity and liver injury score.
• Combined detection of CK18-M30 and total CK18 (M65) can further improve the accuracy of differential diagnosis.
• The antibody shows high specificity, high affinity, and good batch-to-batch consistency in IHC, IF, and WB detection.

5. Product Empowerment

ANT BIO PTE. LTD. provides CK18-M30 Recombinant Rabbit Monoclonal Antibody (SDT-616-2, Cat#: S0B3601).

This product provides key technical support for the above research:

• Specifically recognizes the caspase-cleaved neoepitope of CK18 without binding to intact CK18.
• High affinity and high signal-to-noise ratio, suitable for low-abundance apoptotic signal detection.
• Recombinant production ensures excellent batch consistency and stability.
• Compatible with IHC, IF, WB, and potential quantitative detection kits.
• Effectively supports the non-invasive diagnosis and pathological evaluation of NAFLD/NASH.

6. Brand Mission

ANT BIO PTE. LTD. is a professional supplier of life science reagents.

We focus on providing high-quality antibodies, proteins, kits, and general reagents to support basic research, translational medicine, and diagnostic development.

Our three sub-brands cover a complete research chain:

• Absin: General reagents and kits
• Starter: High-quality antibodies
• UA: Recombinant proteins

7. Related Product List

• CK18-M30 Recombinant Rabbit Monoclonal Antibody (SDT-616-2)
• Apoptosis-related antibody series
• IHC/IF/WB supporting reagents and kits
• General buffers, diluents, and secondary antibodies
• Recombinant proteins for liver disease research

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights